This web page was produced as an assignment for Gen677 at UW-Madison Spring 2010
RNAi
RNAi is used to help determine gene function. This is performed by injecting miRNA and investigating the resulting phenotypes that vary from the wildtype. RNAi experiments have been performed on ABL1 orthologs including in the abl-1 gene in C. elegans. The phenotype was determined using Phenobank as wild-type when performed in post-embryonic C. elegans. RNAi experiments targeting the ABL1 gene have also been done in mice and human cells. One study includes the miRNA-203 which targets ABL1 and BCR-ABL by repressing its expression making it a possible therapeutic for CML. (6) Experiments have been performed to find miRNA to use to treat CML but with difficulty. (4,5)
References
1. GeneCards http://www.genecards.org/
2. Wormbase http://www.wormbase.org/
3. Phenobank http://www.worm.mpi-cbg.de/phenobank2/cgi-bin/MenuPage.py
4. Melo J. V., Hughes, T. P., & Apperley, J. F. (2003). Chronic Myeloid Leukemia. Hematology, 132-152.
5. Leung, R.M. and Whittaker, P.A. (2005). RNA interference: From Gene Silencing to Gene-Specific Therapeutics. Pharmacology & Therapeutics, 222-239.
6. Bueno, M.J., Perez de Castro, I., Gomex de Cedron, M., Santos, J., Calin, G. A., Cigudosa, J.C., Croce, C.M., Fernandez-Piqueras, J., and Malumbres, M. (2008). Genetic and epigenetic silencing of micro-RNA-203 enhances ABL and BCR-ABL oncogene expression. Cancer cell, 13, 467-469.
2. Wormbase http://www.wormbase.org/
3. Phenobank http://www.worm.mpi-cbg.de/phenobank2/cgi-bin/MenuPage.py
4. Melo J. V., Hughes, T. P., & Apperley, J. F. (2003). Chronic Myeloid Leukemia. Hematology, 132-152.
5. Leung, R.M. and Whittaker, P.A. (2005). RNA interference: From Gene Silencing to Gene-Specific Therapeutics. Pharmacology & Therapeutics, 222-239.
6. Bueno, M.J., Perez de Castro, I., Gomex de Cedron, M., Santos, J., Calin, G. A., Cigudosa, J.C., Croce, C.M., Fernandez-Piqueras, J., and Malumbres, M. (2008). Genetic and epigenetic silencing of micro-RNA-203 enhances ABL and BCR-ABL oncogene expression. Cancer cell, 13, 467-469.
